AtriCure, Inc. (ATRC)
Q3 2011 Earnings Conference Call
November 1, 2011 10:00 AM ET
David Drachman – President and CEO
Julie Piton – VP, Finance and Administration and CFO
Jason Mills – Canaccord
Thomas Gunderson – Piper Jaffray
Charley Jones – Barrington Research
Larry Haimovitch – HMTC
Jose Haresco – JMP Securities
Good morning and welcome to AtriCure’s Third Quarter 2011 Earnings Conference Call. My name is (Francine) and I will be your coordinator for the call today. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Mr. David Drachman, President and Chief Executive Officer of AtriCure. Mr. Drachman, please proceed.
Thank you, (Francine). Good morning and welcome to our third quarter earnings conference call. Joining me on the call today is Julie Piton, Vice President of Finance and Administration and Chief Financial Officer. At this time, I would like to turn the call over to Julie for a few introductory comments.
Thank you, Dave, and good morning, everyone. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call Sarah Luken at 513-304-8931 and she will be happy to fax or e-mail you a copy.
Before we begin today, let me remind you that the company’s remarks may include forward-looking statements. These statements include, but are not limited to those that address activity, events, or developments that AtriCure expects, believes, or anticipates will or may occur in the future such as revenue and earnings estimates, other predictions of financial performance, launches of new products, market acceptance of new products, and atrial fibrillation approval by the FDA.